China Sky One Medical, Inc. Obtains Production Rights for Nine...( HARBIN China Nov. 13 /Xinhua-- Ch...)

HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully obtained the rights to nine new drugs under an agreement its subsidiary, Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang"), signed with Shandong Medicine Research & Development Institute.

Under the terms of the agreement, China Sky One obtained all rights to nine new drugs in consideration for a cash payment of RMB 15 million (US $2.2 million; 1 RMB = $0.14 US dollars). Popular in the rural areas of China, the nine new drugs have passed all clinical trials required by the State Food and Drug Administration (SFDA) in China, and have also been approved by the SFDA for production and sale.

-- Oyster Shell Calcium Granules and Oyster Shell Calcium Tablets: for

the treatment of calcifames and osteoporosis, especially for

children, the elderly and pregnant and nursing women;

-- Loquat Syrup: an expectorant for the treatment of tussis and

bronchitis;

-- Flos Lonicerae Syrup: for the treatment coughs, colds, fever and

sore throat;

-- Sedative Bolus: for the treatment of depression and insomnia;

-- Compound Paracetamol and Diphenhydramine Hydrochloride Tablets: for

the treatment of fever, headaches and perennial allergic rhinitis;

-- Compound Tablet of Red Sage Root: for activating blood circulation

to dissipate blood stasis and angina;

-- Compound Aminopyrine Tablets: for the treatment of fever and mild or

modera
'/>"/>